Brief: Kronos Bio Presents Positive Preliminary Data From Phase 1 Dose Escalation Portion Of Phase 1/2 KB-0742 Study At AACR-NCI-EORTC
13/10/2023 17:31
Oct 13 (Reuters) - Kronos Bio Inc KRON.O :
* KRONOS BIO PRESENTS POSITIVE PRELIMINARY DATA FROM PHASE 1
DOSE
ESCALATION PORTION OF PHASE 1/2 KB-0742 STUDY AT AACR-NCI-EORTC
* KRONOS BIO INC - DOSE ESCALATION CONTINUES; DOSING OF
PATIENTS
AT 80 MG DOSE LEVEL IS ONGOING
Source text for Eikon: ID:nGNX9kz9TJ
Further company coverage: KRON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kronos Bio
See all newsBrief: Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing
Brief: Kronos Bio Inc - Enters Transition Agreement With Genentech
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems